💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Oxidronate

CHEMBL2110565 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Technetium oxidronate (99mTc-HDP, hydroxymethylene diphosphonate) is a bone-seeking radiopharmaceutical that adsorbs to hydroxyapatite in areas of osteoblastic activity, used for bone scintigraphy to detect metastases, metabolic bone disorders, and osteomyelitis. It offers favorable bone-to-soft tissue ratios for high-quality skeletal imaging. Its pharmacokinetics are similar to other diphosphonate bone agents but with potentially improved image quality in some settings.

Mecanismo de Ação

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Technetium oxidronate (99mTc-HDP, hydroxymethylene diphosphonate) is a bone-seeking radiopharmaceutical that adsorbs to hydroxyapatite in areas of osteoblastic activity, used for bone scintigraphy to detect metastases, metabolic bone disorders, and osteomyelitis. It offers favorable bone-to-soft tissue ratios for high-quality skeletal imaging. Its pharmacokinetics are similar to other diphosphonate bone agents but with potentially improved image quality in some settings.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Technetium Oxidronate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2110565. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.